Home » Stocks » BSX

Boston Scientific Corporation (BSX)

Stock Price: $43.30 USD 0.17 (0.38%)
Updated May 10, 2021 3:26 PM EDT - Market open
Market Cap 61.27B
Revenue (ttm) 10.12B
Net Income (ttm) 201.00M
Shares Out 1.42B
EPS (ttm) 0.14
PE Ratio 307.06
Forward PE 27.55
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $43.30
Previous Close $43.13
Change ($) 0.17
Change (%) 0.38%
Day's Open 43.16
Day's Range 43.08 - 43.61
Day's Volume 4,375,387
52-Week Range 32.99 - 44.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Like most medical device manufacturers, Boston Scientific Corp. ( BSX , Financial) also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surge...

6 days ago - GuruFocus

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Other stocks mentioned: CNTG, HOLX, INGN, LH, OMI, XRAY
6 days ago - Zacks Investment Research

MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

1 week ago - PRNewsWire

Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).

Other stocks mentioned: ASXC, ISRG, JNJ, SYK
1 week ago - Zacks Investment Research

Bulls bet on Boston Scientific and Las Vegas Sands

YouTube video

"Halftime Report" trader Pete Najarian spots unusual activity in the options market

Other stocks mentioned: LVS
1 week ago - CNBC Television

Boston Scientific Corporation (NYSE: BSX) Q1 sales grew by 5.9% (organically) to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter, better than the consensus e...

1 week ago - Benzinga

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

1 week ago - Zacks Investment Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.

1 week ago - PRNewsWire

Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other stocks mentioned: ABT, ALGN, DGX, HOLX, IART
1 week ago - Zacks Investment Research

Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.

2 weeks ago - Zacks Investment Research

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

EVP&Pres, Periph Intervent of Boston Scientific Corp (30-Year Financial, Insider Trades) Jeffrey B. Mirviss (insider trades) sold 28,123 shares of BSX on 04/15/2021 at an average price of $40.95 a share.

3 weeks ago - GuruFocus

Final Trades: Northrop Grumman, Boston Scientific, Nvidia & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: NOC, NVDA, AAPL
3 weeks ago - CNBC Television

With the trading day about halfway over, the broad markets were pushing much higher with solid gains across the board.

Other stocks mentioned: AMD, INTC, NVDA, AEO, CAKE, CBRL, EW
3 weeks ago - 24/7 Wall Street

Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.

1 month ago - Zacks Investment Research

MARLBOROUGH, Mass., March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter e...

1 month ago - PRNewsWire

Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.

1 month ago - Zacks Investment Research

MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a t...

1 month ago - PRNewsWire

We think that Boston Scientific currently is a better pick compared to Illumina. BSX stock trades at about 5.6x trailing revenues, compared to around 18.8x for ILMN.

Other stocks mentioned: ILMN
1 month ago - Forbes

Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.

1 month ago - Zacks Investment Research

MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Mic...

1 month ago - PRNewsWire

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.

2 months ago - Zacks Investment Research

YOKNEAM, Israel and HONG KONG, March 3, 2021 /PRNewswire/ -- Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical...

2 months ago - PRNewsWire

MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to ...

2 months ago - PRNewsWire

The market is starting to get volatile again and sector rotation is underway. Clear the decks by dumping these stocks to sell for March.

Other stocks mentioned: BIIB, DUK, GSK, LVS, RTX, T
2 months ago - InvestorPlace

We think that ​Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific.

Other stocks mentioned: HSIC
2 months ago - Forbes

Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.

Other stocks mentioned: COO, HOLX, LH, MASI, MDT, XRAY
2 months ago - Zacks Investment Research

Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.

Other stocks mentioned: IBB, XBI
2 months ago - InvestorPlace

Whether in transportation, manufacturing or healthcare, don't touch any of these 14 AI-related stocks with a 10-foot pole. Here's why.

Other stocks mentioned: ATEX, BIIB, LUV, T, TNAV, XRX
2 months ago - InvestorPlace

MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice presi...

2 months ago - PRNewsWire

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

3 months ago - Zacks Investment Research

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

3 months ago - Zacks Investment Research

Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Boston Scientific (NYSE:BSX) fell 2.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 50.00% year over year to $0.23, which missed ...

3 months ago - Benzinga

MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) per...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 2, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

3 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - February 2, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between Apr...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX)...

3 months ago - Newsfile Corp

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Bosto...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...

3 months ago - Newsfile Corp

NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation...

3 months ago - GlobeNewsWire

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action...

3 months ago - PRNewsWire

NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 an...

3 months ago - GlobeNewsWire

NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and ce...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) betwee...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...

3 months ago - Newsfile Corp

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]

Industry
Medical Devices
IPO Date
May 18, 1992
CEO
Michael Mahoney
Employees
38,000
Stock Exchange
NYSE
Ticker Symbol
BSX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 27 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is 49.04, which is an increase of 13.27% from the latest price.

Price Target
$49.04
(13.27% upside)
Analyst Consensus: Strong Buy